These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8229026)

  • 1. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.
    J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1157-63. PubMed ID: 8229026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Trial of Thymectomy in Myasthenia Gravis.
    Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BR; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Garcia Ramos GS; Verschuuren JJ; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Odenkirchen J; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
    N Engl J Med; 2016 Aug; 375(6):511-22. PubMed ID: 27509100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticosteroids for myasthenia gravis.
    Schneider-Gold C; Gajdos P; Toyka KV; Hohlfeld RR
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002828. PubMed ID: 15846640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
    Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
    J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis.
    Scherpbier HJ; Oosterhuis HJ
    Clin Neurol Neurosurg; 1987; 89(3):145-50. PubMed ID: 3665287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azathioprine in the treatment of myasthenia gravis.
    Witte AS; Cornblath DR; Parry GJ; Lisak RP; Schatz NJ
    Ann Neurol; 1984 Jun; 15(6):602-5. PubMed ID: 6742794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
    Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
    N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis.
    Heckmann JM; Rawoot A; Bateman K; Renison R; Badri M
    BMC Neurol; 2011 Aug; 11():97. PubMed ID: 21819556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
    Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
    Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
    Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial.
    Sharshar T; Porcher R; Demeret S; Tranchant C; Gueguen A; Eymard B; Nadaj-Pakleza A; Spinazzi M; Grimaldi L; Birnbaum S; Friedman D; Clair B;
    JAMA Neurol; 2021 Apr; 78(4):426-433. PubMed ID: 33555314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose immunosuppressive therapy in generalised myasthenia gravis--a 2-year follow-up study.
    Heckmann JM; LeePan EB; Eastman RW
    S Afr Med J; 2001 Sep; 91(9):765-70. PubMed ID: 11680327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of myasthenia gravis by immunosuppressive non-steroidal drugs].
    De Assis JL; Marchiori PE; Scaff M; Zambon AA
    Arq Neuropsiquiatr; 1986 Jun; 44(2):109-16. PubMed ID: 3800686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmapheresis as a guide for azathioprine therapy in prednisone-resistant myasthenia gravis.
    Rodnitzky RL; Bosch EP
    Muscle Nerve; 1981; 4(6):529-30. PubMed ID: 7311992
    [No Abstract]   [Full Text] [Related]  

  • 16. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
    Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
    Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sweet syndrome as a manifestation of azathioprine hypersensitivity.
    El-Azhary RA; Brunner KL; Gibson LE
    Mayo Clin Proc; 2008 Sep; 83(9):1026-30. PubMed ID: 18775203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined plasma exchange and immunosuppression in myasthenia gravis.
    Newsom-Davis J; Vincent A
    Lancet; 1979 Sep; 2(8144):688. PubMed ID: 90770
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antibody-controlled cytostatic therapy of malignant thymoma with concomitant myasthenia gravis].
    Schumm F; Brinkmann A; Fateh-Moghadam A
    Dtsch Med Wochenschr; 1984 Aug; 109(33):1244-6. PubMed ID: 6547902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing outcome of prednisone dose reduction in myasthenia gravis.
    Miano MA; Bosley TM; Heiman-Patterson TD; Reed J; Sergott RC; Savino PJ; Schatz NJ
    Neurology; 1991 Jun; 41(6):919-21. PubMed ID: 2046940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.